Clinical trial Recruiting at 1 site Interventional Ages 18 to 40 Women only

Real-time glucose monitoring for pregnant women with type 2 diabetes

Official title: Effect of Real Time Continuous Glucose Monitoring System on Management of Women With Type 2 Diabetes Mellitus During Pregnancy in a Multidisciplinary Comprehensive System

Run by Peking University Third Hospital · NCT05947916 · Data updated 2026-11-12

This study tests whether real-time continuous glucose monitoring helps pregnant women with type 2 diabetes keep glucose in range better than standard self-checks, aiming to improve outcomes for mothers and babies.

Quick facts

Study typeInterventional
Ages18 Years to 40 Years
SexWomen only
Enrollment240 (estimated)
SponsorPeking University Third Hospital
Academic / other
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedJanuary 30, 2024
Main results expectedDecember 31, 2025
Study endsDecember 31, 2026
Registry record updatedJuly 2, 2026
Trial IDNCT05947916 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Pregnant women with type 2 diabetes in early pregnancy (4–26 weeks) with suboptimal glycemic control requiring intensive insulin therapy.

Probably not a fit

Patients without access to real-time CGM devices or with conditions limiting insulin therapy may derive no additional benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, open-label study compares real-time continuous glucose monitoring (CGM) with conventional self-monitoring of blood glucose in pregnant women with type 2 diabetes on intensive insulin therapy. Participants are randomized to receive CGM or standard SMBG, with management guided by multidisciplinary care. The trial evaluates maternal and infant outcomes, safety, and glucose control over pregnancy. Recruitment targets 120 participants in early pregnancy, across urban and affiliated hospital sites in Beijing. The study builds on prior CGM use in diabetes to assess pregnancy-specific benefits and feasibility.

Why it matters

Potential benefit: If successful, real-time CGM could improve glucose control during pregnancy and reduce adverse outcomes for both mother and child.

How similar studies have gone: Previous CGM studies in diabetes show promise, but data specific to pregnancy and type 2 diabetes is still developing, making this relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* A clear history of type 2 diabetes, or a history of type 2 diabetes diagnosed in early pregnancy
* Singleton gestation at 4-26 weeks, with substandard glycemic control (i.e., fasting glucose \> 5.3 mmol/L, and or 1 hour postprandial glucose \> 7.8 mmol/L, and or 2 hours postprandial glucose \> 6.7 mmol/L) after lifestyle intervention ± basal insulin therapy, as assessed by the endocrinology department. Patients who need insulin regimen with basal plus meal or insulin pump regimen.
* Patients are willing and committed to establish and follow up in the obstetrics and gynecology departments of Peking University Third Hospital, Haidian District Hospital and Yanqing District Hospital during pregnancy, and are willing to provide information on obstetric examination and perinatal medical records if they are transferred to the hospital for special reasons for follow-up or delivery.
* Voluntarily participate in the study, examine and follow up according to this project and sign informed consent.
* Able to pass the screening period Adherence evaluation

Exclusion Criteria:

* Patients with type 1 diabetes, specific type of diabetes or gestational diabetes
* Pregnancy with severe comorbidities or diabetic complications for which obstetrics does not recommend continuation of pregnancy, including but not limited to the following: proliferative retinopathy, chronic kidney disease (eGFR less than 60 mL/min/1.73± massive proteinuria), known coronary and cerebrovascular disease, autoimmune system disease and receiving exogenous glucocorticoids or immunosuppressive therapy.
* Patients who have been hospitalized for psychiatric treatment within 6 months prior to enrollment or are still on psychiatric medications.
* Patients who have received other interventional studies.

Where it's running

  • Peking University Third Hospital
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.